ORX-750

Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders. This milestone triggers a payment of US$3.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognised as revenue in Q4 FY2025. -ENDS- About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, and powered by its unique NxWave™ GPCR structure-based drug discovery platform, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma QUVIVIQ™ is trademark of Idorsia Ltd. Enquiries: Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Alkermes is planning to start a global phase 3 program for its narcolepsy drug candidate in the first quarter of 2026. \n Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its hopes of being first to market in the indication.The trial randomized 93 people with narcolepsy type 2 (NT2) to receive one of three doses of alixorexton or placebo. After eight weeks of once-daily oral dosing, Alkermes saw significant improvements on a test of wakefulness on the top two doses of alixorexton compared to placebo, achieving one of its co-primary endpoints. Only the top dose hit the other primary endpoint, which tested excessive daytime sleepiness.No patients on alixorexton had serious treatment-emergent adverse events or clinically meaningful, treatment-related changes on ophthalmic exams. Eye safety has been a focus since Jazz Pharmaceuticals stopped a phase 1 trial of its narcolepsy prospect JZP441 in 2023 over reports of “visual disturbances.”Alixorexton, like JZP441, is an orexin 2 receptor (OX2R) agonist. Dealing with the safety signal, Jazz is still back in phase 1. But Alkermes faces more advanced rivals for the narcolepsy market. Takeda is ready to seek approval for its lead OX2R asset oveporexton in narcolepsy type 1 (NT1) patients. Alkermes posted a win for alixorexton in NT1 in July. Takeda halted development of oveporexton in NT2 last year, leaving its hopes of challenging Alkermes in the indication on the phase 2 TAK-360. Centessa Pharmaceuticals has shown ORX750 could be a threat to Alkermes in NT1 and NT2, with the company recently sharing phase 2a data on the OX2R agonist in both indications.Guggenheim Securities analysts said in a note to investors last week that Centessa executives “appeared confident” of starting a registrational study in the first quarter of next year. The timeline puts Centessa neck and neck with Alkermes, which is planning to start its global phase 3 program in the same quarter. Craig Hopkinson, M.D., Alkermes’ chief medical officer, discussed the phase 3 plans with analysts.“We\'ve always believed in the value of providing a range of doses to accommodate disease variability and patient preference. We are even more convinced of that now,” Hopkinson said on the call. “The nuances and underlying trends of the data provide an opportunity to amplify the signal,” Hopkinson added. “In phase 3, we plan to advance a range of doses, including once-daily administration as well as split-dosing regimens.”Alkermes has identified split dosing as a way to address the variability in wakefulness seen at some time points. While responses were consistent two and four hours after dosing, they began to diverge after six and eight hours. Hopkinson declined to answer an analyst’s question about the potential magnitude of the benefit of splitting the dose, citing “proprietary reasons.”